Home Stock

Stock Research: Chunghwa Chemical Synthesis & Biotech

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Chunghwa Chemical Synthesis & Biotech

TAI:1762 TW0001762003
32
  • Value
    78
  • Growth
    3
  • Safety
    Safety
    41
  • Combined
    29
  • Sentiment
    43
  • 360° View
    360° View
    32
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD. is a Taiwan-based company manufacturing and distributing biotechnology and chemical synthetic products. The company's main businesses include biotechnology products (e.g., pravastatin, rapamycin, tacrolimus) and non-biotechnology products (e.g., methocarbamol, guaifenesin), applied in drugs for various treatments including cough, diabetes, cardiovascular diseases, high blood pressure, and immune system diseases. It operates in domestic and overseas markets, including Asia, the Americas, and Europe. In the last fiscal year, the company had a market cap of $73 million, profits of $12 million, and revenue of $41 million.

more

ANALYSIS: With an Obermatt 360° View of 32 (better than 32% compared with alternatives), overall professional sentiment and financial characteristics for the stock Chunghwa Chemical Synthesis & Biotech are below the industry average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for Chunghwa Chemical Synthesis & Biotech. Only the consolidated Value Rank has an attractive rank of 78, which means that the share price of Chunghwa Chemical Synthesis & Biotech is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is lower than for 78% of alternative stocks in the same industry. All other consolidated ranks are below average. The consolidated Growth Rank has a low rank of 3, which means that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. The consolidated Safety Rank has a riskier rank of 41, meaning the company has a riskier financing structure than 59% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, professionals are more pessimistic about the stock than for 57% of alternative investment opportunities, reflected in the consolidated Sentiment Rank of 43. ...read more

more
Strongest Rank Analyst Opinions
Weakest Rank Price vs. Earnings (P/E)
Country Taiwan
Industry Pharmaceuticals
Size X-Small
Website ccsb.com.tw
Index
Chunghwa Chemical Synthesis & Biotech stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 13-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
78 54 80 73
Growth
3 14 47 100
Safety
Safety
41 38 61 72
Sentiment
43 70 41 100
360° View
360° View
32 38 64 100
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
1 20 20 97
Opinions Change
50 50 50 50
Pro Holdings
n/a 52 30 98
Market Pulse
92 91 100 100
Sentiment
43 70 41 100
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
78 54 80 73
Growth
3 14 47 100
Safety Safety
41 38 61 72
Combined
29 13 79 100
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
41 51 57 63
Price vs. Earnings (P/E)
100 26 97 95
Price vs. Book (P/B)
94 83 65 63
Dividend Yield
1 64 67 65
Value
78 54 80 73
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
1 22 67 98
Profit Growth
34 28 15 26
Capital Growth
9 54 81 96
Stock Returns
13 16 39 91
Growth
3 14 47 100
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
59 33 47 94
Refinancing
67 63 57 27
Liquidity
10 31 61 61
Safety Safety
41 38 61 72

Similar Stocks

Discover high‑ranked alternatives to Chunghwa Chemical Synthesis & Biotech and broaden your portfolio horizons.

Daiwa House

TYO:1925
Country: Japan
Industry: Electric Utilities
Size: XX-Large
Full Stock Analysis

Kinden

TYO:1944
Country: Japan
Industry: Construction & Engineering
Size: X-Large
Full Stock Analysis

Shionogi

TYO:4507
Country: Japan
Industry: Pharmaceuticals
Size: X-Large
Full Stock Analysis

Phison Electronics

TWO:8299
Country: Taiwan
Industry: Semiconductors
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

The only strength is good value. All other factors (growth, safety, and sentiment) are below average. This stock is highly sensitive to a crisis and is not advisable. Avoid unless you have solid, independent reasons to believe a significant turnaround is imminent.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews